ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0484

Relationship Between Paraoxonase-1 Genotype, Activity, and Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Receiving Tofacitinib

Christina Charles-Schoeman1, Craig Hyde2, Shunjie Guan3, Neil Parikh1, Jennifer Wang1, Ani Shahbazian1, Lori Stockert4 and John Andrews4, 1University of California, Los Angeles, Los Angeles, CA, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Cambridge, MA, 4Pfizer Inc, Collegeville, PA

Meeting: ACR Convergence 2020

Keywords: Biomarkers, Cardiovascular, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes II: The Heart of the Matter (0484–0488)

Session Type: Abstract Session

Session Time: 4:00PM-4:50PM

Background/Purpose: Paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)‑associated enzyme with paraoxonase, lactonase, and arylesterase activities. PON1 contributes to the antioxidant properties of HDL, and is being investigated for its atheroprotective properties.1 Patients (pts) with RA that are homozygous for the RR genotype of the Q192R gene polymorphism on PON1 (rs662) have increased paraoxonase activity, and a lower risk of carotid plaques, vs those with QQ or QR genotypes.2 Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post hoc analysis investigated the relationship between PON1 genotype/activity and risk of major adverse cardiovascular events (MACE) in the tofacitinib RA clinical program.

Methods: Data were pooled from pts enrolled in nine Phase 2/3 studies of tofacitinib in RA. Enzyme activities in pt plasma samples were measured at individual study baseline (BL) and at follow‑up visits using three substrates: paraoxon (paraoxonase activity), dihydrocoumarin (lactonase activity), and phenylacetate (arylesterase activity). The effect of the PON1 Q192R genotype (QQ, QR, or RR) on BL paraoxonase/lactonase/arylesterase activity was determined using linear regression for each study with age and sex as covariates, and then fixed‑effect meta-analysis assessed effects across studies. The risk of MACE by enzyme activity was determined using Cox proportional hazards regression stratified by clinical studies. Univariate regression against BL enzyme activity and other risk factors, as well as both minimally and fully adjusted multivariable regressions against time-varying enzyme activity, are presented.

Results: The analysis included 1,969 pts with RA who received ≥ 1 dose of tofacitinib and had PON1 activity measures available at BL; 39 pts had ≥ 1 MACE event. Compared with the QQ genotype, the RR genotype had a highly significant positive association with BL paraoxonase activity, and a highly significant negative association with BL lactonase and arylesterase activity (Figure 1). A univariate analysis identified several BL covariates significantly associated with risk of MACE (Figure 2a). Time-varying models found a highly significant association of increased paraoxonase activity over time with lower risk of future MACE, even after controlling for low-density lipoprotein or HDL cholesterol levels, and other traditional cardiovascular (CV) risk factors identified in univariate analysis (Figure 2b), with similar findings for lactonase and arylesterase (data not shown).

Conclusion: Higher activity of the HDL-associated protein, PON1, over time was associated with a significantly reduced risk of future MACE in pts with RA receiving tofacitinib, after controlling for traditional CV risk factors and cholesterol levels. Further investigation of PON1 as a novel functional lipid biomarker to assess CV risk in RA pts is warranted.

  1. Mackness M, Mackness B. Gene 2015; 567: 12-21.
  2. Charles-Schoeman C et al. Arthritis Rheum 2013; 65: 2765-2772.

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by Jennifer Higginson, PhD, CMC Connect, and funded by Pfizer Inc.

Figure 1

Figure 2


Disclosure: C. Charles-Schoeman, AbbVie, 2, 5, Regeneron-Sanofi, 5, Gilead, 5, Bristol-Myers Squibb, 2, Pfizer Inc, 2, 5; C. Hyde, Pfizer Inc, 1, 3; S. Guan, Pfizer Inc, 1, 3; N. Parikh, None; J. Wang, None; A. Shahbazian, None; L. Stockert, Pfizer Inc, 1, 3; J. Andrews, Pfizer Inc, 1, 3.

To cite this abstract in AMA style:

Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype, Activity, and Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Receiving Tofacitinib [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/relationship-between-paraoxonase-1-genotype-activity-and-major-adverse-cardiovascular-events-in-patients-with-rheumatoid-arthritis-receiving-tofacitinib/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relationship-between-paraoxonase-1-genotype-activity-and-major-adverse-cardiovascular-events-in-patients-with-rheumatoid-arthritis-receiving-tofacitinib/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology